NeoGenomics, Inc. revised earnings guidance for the fiscal year 2023. For the year, the company expects consolidated revenue to be in the range of $565 million to $575 million against previous guidance range of $555 million to $565 million. Net loss to be in the range of $107 million to $100 million against previous guidance range of $116 million to $108 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14 USD | +1.27% | +0.83% | -13.44% |
28/05 | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.44% | 176.63Cr | |
-25.19% | 766.53Cr | |
+69.34% | 438.4Cr | |
-7.18% | 251.96Cr | |
-44.46% | 222.8Cr | |
-21.62% | 152.06Cr | |
+17.46% | 121.14Cr | |
-43.89% | 114.16Cr | |
+19.93% | 100Cr | |
-6.62% | 95Cr |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023